Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $243.80 million. The enterprise value is $106.08 million.
| Market Cap | 243.80M |
| Enterprise Value | 106.08M |
Important Dates
The last earnings date was Tuesday, May 14, 2024, before market open.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 58.89 million shares outstanding. The number of shares has increased by 45.08% in one year.
| Shares Outstanding | 58.89M |
| Shares Change (YoY) | +45.08% |
| Shares Change (QoQ) | +15.31% |
| Owned by Insiders (%) | 19.85% |
| Owned by Institutions (%) | 38.37% |
| Float | 38.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.10 |
| Forward PS | 53.11 |
| PB Ratio | 1.32 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.19, with a Debt / Equity ratio of 0.11.
| Current Ratio | 12.19 |
| Quick Ratio | 11.77 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.00% and return on invested capital (ROIC) is -32.62%.
| Return on Equity (ROE) | -39.00% |
| Return on Assets (ROA) | -30.60% |
| Return on Capital (ROIC) | -32.62% |
| Revenue Per Employee | $322,920 |
| Profits Per Employee | -$1.16M |
| Employee Count | 50 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.86% in the last 52 weeks. The beta is 1.45, so Pyxis Oncology's price volatility has been higher than the market average.
| Beta (1Y) | 1.45 |
| 52-Week Price Change | +11.86% |
| 50-Day Moving Average | 4.70 |
| 200-Day Moving Average | 3.08 |
| Relative Strength Index (RSI) | 40.80 |
| Average Volume (30 Days) | 714,627 |
Short Selling Information
The latest short interest is 1.85 million, so 3.14% of the outstanding shares have been sold short.
| Short Interest | 1.85M |
| Short Previous Month | 2.21M |
| Short % of Shares Out | 3.14% |
| Short % of Float | 4.78% |
| Short Ratio (days to cover) | 2.96 |
Income Statement
In the last 12 months, Pyxis Oncology had revenue of $16.15 million and -$57.80 million in losses. Loss per share was -$1.36.
| Revenue | 16.15M |
| Gross Profit | 15.67M |
| Operating Income | -66.85M |
| Pretax Income | -57.80M |
| Net Income | -57.80M |
| EBITDA | -54.27M |
| EBIT | -57.80M |
| Loss Per Share | -$1.36 |
Balance Sheet
The company has $158.50 million in cash and $20.78 million in debt, giving a net cash position of $137.72 million or $2.34 per share.
| Cash & Cash Equivalents | 158.50M |
| Total Debt | 20.78M |
| Net Cash | 137.72M |
| Net Cash Per Share | $2.34 |
| Equity / Book Value | 184.16M |
| Book Value Per Share | 3.13 |
| Working Capital | 158.24M |
Cash Flow
In the last 12 months, operating cash flow was -$64.58 million and capital expenditures -$2.56 million, giving a free cash flow of -$67.14 million.
| Operating Cash Flow | -64.58M |
| Capital Expenditures | -2.56M |
| Free Cash Flow | -67.14M |
| FCF Per Share | -$1.31 |
Margins
Gross margin is 97.06%, with operating and profit margins of -414.02% and -358.00%.
| Gross Margin | 97.06% |
| Operating Margin | -414.02% |
| Pretax Margin | -358.00% |
| Profit Margin | -358.00% |
| EBITDA Margin | -336.12% |
| EBIT Margin | -358.00% |
| FCF Margin | -415.80% |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -45.08% |
| Shareholder Yield | -45.08% |
| Earnings Yield | -23.71% |
| FCF Yield | -27.54% |
Analyst Forecast
The average price target for Pyxis Oncology is $9.83, which is 136.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.83 |
| Price Target Difference | 136.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -2.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pyxis Oncology has an Altman Z-Score of 2.29. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | n/a |